MARKET

DNLI

DNLI

Denali
NASDAQ

Real-time Quotes | Nasdaq Last Sale

54.01
-2.03
-3.62%
After Hours: 54.01 0 0.00% 16:19 04/16 EDT
OPEN
56.91
PREV CLOSE
56.04
HIGH
57.22
LOW
53.08
VOLUME
298.95K
TURNOVER
--
52 WEEK HIGH
93.94
52 WEEK LOW
18.45
MARKET CAP
6.53B
P/E (TTM)
337.35
1D
5D
1M
3M
1Y
5Y
Global FRP Tanks Market Size 2021 Industry Share, Growth, Business Challenges, Investment Opportunities, Demand, Key Manufacturers and 2026 Forecast Research Report
Apr 14, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." The “FRP Tanks Market” Research Report...
The Express Wire · 3d ago
FRP Tank Market Will Record an Upsurge in Revenue during 2021-2026
Market Insight Reports · 4d ago
Denali Therapeutics Inc (DNLI) COO and Secretary Alexander O. Schuth Sold $560,900 of Shares
GuruFocus News · 04/06 08:01
FRP Vessels Market 2021 Size, Share, Research Methodology, Revenue By 2027
Apr 02, 2021 (Market Insight Reports) -- Increasing demand for FRP vessels from the automotive industry is one of the significant factors driving the market....
Market Insight Reports · 04/02 15:15
Replay: Investing in Alzheimer’s Treatment — Jupiter Orphan Therapeutics CEO Joins Fireside Chat
Christer Rosén, Chairman-CEO & Founder of Jupiter Orphan Therapeutics, Inc, Raymond “Scott” Turner MD, Professor Neurology, Georgetown University (Alzheimer’s scientist) and Mark Dant, Executive Director, Ryan Foundation IPO Edge, in partnership with The P...
IPO-Edge.com · 03/30 17:23
Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer
PR Newswire · 03/30 14:30
Press Release: Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer
Dow Jones · 03/30 13:30
Denali Therapeutics Inc. (DNLI) Down 12.3% Since Last Earnings Report: Can It Rebound?
Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 03/27 16:31
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DNLI. Analyze the recent business situations of Denali through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DNLI stock price target is 81.00 with a high estimate of 106.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 253
Institutional Holdings: 89.47M
% Owned: 73.95%
Shares Outstanding: 120.98M
TypeInstitutionsShares
Increased
64
15.61M
New
58
1.88M
Decreased
65
9.83M
Sold Out
24
1.36M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/Independent Director
Vicki Sato
Chairman/Independent Director
vicki Sato
President/Chief Executive Officer/Co-Founder/Director
Ryan Watts
Co-Founder/Chief Operating Officer/Secretary
Alexander Schuth
Chief Financial Officer/Treasurer
Steve Krognes
Other
Carole Ho
Director
Nancy Thornberry
Independent Director
Douglas Cole
Independent Director
Jennifer Cook
Independent Director
Jay Flatley
Independent Director
Peter Klein
Independent Director
Robert Nelsen
Independent Director
David Schenkein
Independent Director
Marc Tessier-Lavignec
No Data
About DNLI
Denali Therapeutics Inc. is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease. The Company has selected approximately four specific pathways that are implicated as triggers or effectors of neurodegeneration, including degenogenes (genes that cause neurodegenerative disease when mutated), defective intracellular trafficking, glial dysfunction and axon degeneration. The Company’s development programs include Lysosomal Function Pathway, Glial Biology Pathway, and Cellular Homeostasis Pathway. Its product pipeline includes drug candidates such as DNL201, DNL 151, ATV:aSyn, ETV:IDS, DNL747, and ATV:TREM2.

Webull offers kinds of Denali Therapeutics Inc stock information, including NASDAQ:DNLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DNLI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DNLI stock methods without spending real money on the virtual paper trading platform.